Skip to content

TAiloring LImb length based on total small bowel Lengthin Omega-loop gastric bypass suRgery : the TAILOR study

Tailoring Limb length based on total small bowel length in omega-loop gastric bypass

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27559
Enrollment
212
Registered
2019-08-09
Start date
2020-03-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

class III obesity or class II with co-morbidities e.g diabetes, hypertension, sleep apnea, arthrosis

Interventions

Patients will be randomly allocated to one of the two treatment arms : - 1. A standard BP-limb length of 150 cm - 2. A BP-limb length depending on total small bowel length (TSBL) measured during the s

Sponsors

Medisch Center Leeuwarden
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Agreed to have mini-gastric bypass surgery - Age between 18 and 65 - BMI > 40 kg/m2 or - BMI > 35 kg/m2 with co-morbidity : diabetes, hypertension, OSAS, arthrosis - Willing to participate with written informed consent before start of the surgery - A completely measured total small bowel during surgery - No pre-operative deficiencies of vit B12, vit D and iron, measured with ferritin - No use of extra (multi-)vitamin supplements with exception of vit D max 800 IU/day - Able to swallow the multivitamin FFM WLS primo (tested before surgery)

Exclusion criteria

Exclusion criteria: - BMI > 50 Kg/m2 - Known gastro-intestinal disease or history of gastro-intestinal disease, e.g. celiac disease, inflammatory bowel disease - Known addiction behaviour - Suspected compliance problems - Intolerance to Fitforme Primo multivitamin - Pregnancy planning within the first two years after surgery - Renal or hepatic insufficiency - Former abdominal surgery unabling the measurement of the small bowel during laparoscopic surgery - Parenteral use of vit B12

Design outcomes

Primary

MeasureTime frame
Percent total weight loss (%TWL) at 5 years. Assumptions : Control group : TWL of 35% (SD 12%) Experimental group : TWL of 40% (SD 12 or 9%) (Absolute difference TWL 5% with possible smaller SD) Definition : TWL = ([initial weight – attained weight]/ initial weight) * 100

Secondary

MeasureTime frame
1) Percent of total weight loss (%TWL) at 1,2,3,and 4 years. 2) Percent excess weight loss (%EWL) at 1,2,3, 4 and 5 years. Definition: %EWL (Initial Weight – Postop Weight) / (Initial Weight – Ideal Weight) (ideal weight is defined by the weight corresponding to a BMI of 25 kg/m2 ) 3) Percent excess BMI loss (%EBMIL) at 1,2,3, 4 and 5 years. Definition: %EBMIL (?BMI / (Initial BMI – 25)) * 100] 4) Proportion of patients with 22 = BMI = 30 Kg/m2 at 1,2,3, 4 and 5 years 5) Mean number of daily bowel movements in the last two weeks at 6 months, 1,2,3, 4 and 5 years. 6) Mean number of days with daily bowel movements > 3 in the last two weeks at 6 months, 1,2,3, 4 and 5 years. 7) Quality of life measured by the RAND-36 questionnaire at 6 months, 1,2,3, 4 and 5 years. 8) percentage of patients experiencing moderate to severe dumping symptoms defined by the Dumping Severity Score (DSS) at 6 months, 1,2,3, 4 and 5 years. Moderate to severe is defined as 3 or more dumping symptoms with a severity score of 2 or 3 on a 4-point Likert scale. Symptoms are divided in two categories, e.g. early and late,as described by Emous et.al. (7) 9) percentage of patients who have neither deficiencies of iron, nor vit. D, nor vit B12 without extra suppletion, at 6 months, 1,2,3, 4 and 5 years . Deficiencies are based on the local normal laboratory values. 10) Proportion of patients who have a deficiency at 6 months, 1,2,3, 4 and 5 years, or received extra suppletion for: - iron (ferritin) - vitamin B12 - vitamin D3 - Vitamin B1 - Vitamin B6 - Folic acid - Vitamin A - Vitamin D - Calcium - Phosphate - Albumin - Zinc - Copper - Selenium 11)Proportion of patients at 1,2,3, 4 and 5 years without diabetes, both with remission and without de novo, defined as an HbA1c less than 48 mmol/mol without diabetes medication in the last 6 months. 12)Proportion of patients at one year and two years with improvement of diabetes, defined as a reduction of HbA1c of 10mmol/mol or more but not reaching remiss

Contacts

Public ContactLoek de Heide

Medisch Centrum Leeuwarden

l.de.heide@mcl.nl0582866666

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)